相关实验视频
Updated: Sep 15, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.2K
德乌克拉维西替尼在患有牛皮的患者中改善了间歇性肺炎,并减少了KL-6:一个病例报告
Yoshihito Mima1,2, Tsutomu Ohtsuka2, Norimichi Akiyama3
1Department of Dermatology, Tokyo Metropolitan Police Hospital, Tokyo, Japan.
Clinical, cosmetic and investigational dermatology
|July 14, 2025
概括
杜克拉维西替尼是一种选择性氨酸激酶2 (TYK2) 抑制剂,在患有牛皮的患者中显示出改善间歇性肺炎 (IP) 的潜力. 这表明TYK2抑制剂可能对肺炎和纤维化等相关疾病有好处.
科学领域:
- 皮肤病学和肺病学
- 免疫学和药理学
背景情况:
- 牛皮是一种免疫介导的皮肤疾病,与T辅助细胞17 (Th17) 和系统性并发症有关.
- 间歇性肺炎 (IP) 涉及肺炎和纤维化,细胞因子在其发病过程中起着至关重要的作用.
- 牛皮患者患有IP的风险增加,可能是由于共享的互白素-23/互白素-17 (IL-23/IL-17) 通路.
研究的目的:
- 报告一个牛皮病例与间歇性肺炎治疗deucravacitinib.
- 探索deucravacitinib在改善间歇性肺炎中的潜在治疗作用.
- 调查deucravacitinib对皮肤和肺部表现的影响.
主要方法:
- 一个病例报告详细介绍了患有牛皮和间歇性肺炎的患者.
- 用deucravacitinib治疗,这是一种选择性口服氨酸激酶2 (TYK2) 抑制剂.
- 监测临床症状,皮肤发现,肺部成像和KL-6水平.
主要成果:
- 患者在牛皮皮肤病变和间歇性肺炎发现均显著改善.
- 德乌克拉维西提尼治疗后,KL-6水平,PI的标志物,下降了.
- 德乌克拉维西丁尼有效地准了与牛皮和潜在的IP有关的IL-23和I型干扰素通路.
结论:
- 在患有牛皮的患者中,deucravacitinib可能为间歇性肺炎提供治疗益处.
- 阻断TYK2信号通路可以减轻IP中的T细胞驱动的炎症和纤维化.
- 需要进一步的研究和案例研究来证实TYK2抑制剂对间歇性肺炎的临床效用.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
272
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
272
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
204
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
204
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
237
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
237
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
265
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
265
Antiasthma Drugs: Leukotriene Modifiers
486
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
486
Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239

